Pure erythrocytosis classified according to erythropoietin titers. Cervantes F, Barosi G, Demory JL, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. The myeloproliferative disorders, excluding chronic myelogenous leukemia, are chronic diseases with a variable propensity to convert into acute myelogenous leukemia. Patients with polycythemia vera and essential thrombocythemia have marked increases of red cell and platelet production, respectively.
Treatment is directed at reducing the excessive numbers of blood cells.
Bleeding and thrombosis in the myeloproliferative disorders. The PDQ editorial boards use a formal ranking system to help the reader judge the strength of evidence linked to the reported results of a therapeutic strategy. In addition, progressive splenomegaly or pruritus not controllable by antihistamines may persist despite control of the hematocrit by phlebotomy. If phlebotomy becomes impractical, therapy with the radioisotope phosphorous-32 or alkylating agents can be used to control the disease. Additional follow-up and other confirmatory trials are required.